Clinical Trial Update: The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial assessing the immunogenicity and safety of a 60 mcg/30 mcg recombinant hepatitis B vaccine in individuals who did not respond to routine hepatit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• 60 mcg/30 mcg recombinant hepatitis B vaccine (recombinant hepatitis B vaccine)

Snippet

Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Conditions: Hepatitis b | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2012-04-23